{"name":"MaaT Pharma","slug":"maat-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Autologous Fecal Microbiota Transplantation","genericName":"Autologous Fecal Microbiota Transplantation","slug":"autologous-fecal-microbiota-transplantation","indication":"Moderate to severe Clostridioides difficile infection","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"MaaT013","genericName":"MaaT013","slug":"maat013","indication":"Steroid-refractory acute graft-versus-host disease (aGvHD)","status":"phase_3"}]}],"pipeline":[{"name":"Autologous Fecal Microbiota Transplantation","genericName":"Autologous Fecal Microbiota Transplantation","slug":"autologous-fecal-microbiota-transplantation","phase":"phase_2","mechanism":"Autologous Fecal Microbiota Transplantation involves transplanting a patient's own fecal microbiota to restore a balanced gut microbiome.","indications":["Moderate to severe Clostridioides difficile infection","Ulcerative colitis"],"catalyst":""},{"name":"MaaT013","genericName":"MaaT013","slug":"maat013","phase":"phase_3","mechanism":"MaaT013 is a microbiota-based therapeutic that restores a healthy gut microbiome composition to treat immune-mediated diseases.","indications":["Steroid-refractory acute graft-versus-host disease (aGvHD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQY2IwQlVIbmN2YjdvYlNtTHZ4SXE2SUZxbFRZc2t4eUlYV01Qck9Xc3FPVWhYbnBZczRsX0RaZzR3ZE1ENi1oeDFfbmVzWWExS0ctV0RvLUN1UE40S0FfMmx1T00ycVhmZWMzalRnSE50RXU1eWplQV9FV3hGSzg0NkY2R0NnQlJvbE5fV0VxUWdYSWZXelVybXo4S0xzSjZvT2g2Ni1FWTB3OGVBNm1SNEdRWGlMRnE5STh4NHhuM2hBeUllTF9tWkhjeWxjeFJDVXJzLTFmc0lMeG9Vd0pwU2hMOVJjQ29WV0VnMGxOYnNwQ1k3UFpHS2FJTzYzSDg0NEpHOFYyNjh2ZnFFZWY0?oc=5","date":"2026-04-01","type":"trial","source":"BioSpace","summary":"MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal - BioSpace","headline":"MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNV0hwTllLczRVd3BaWVpNQVJsTDZwU1ljc05VbFBCSUwxTUpwSlBqdkF3NDhmbTJtd0ZWLWprX0NzSWJ3SkdHdE9MeVdKd1hpNGFYMTF4WEFTLUEzZUszYTlBMzBLNDU0R0pnSnllTXRkQWNObnNTRzlzeUtqU1RBZEpXV29OdmpKeWVZVDVkRlZCSWdKcF9jUmJkS0NPSjBVbmlwZF9SemUzM05mWEFKX3dKc0hCSmNTcWxQVkp3TUlJMmJvR0hmT1Q5MVpfREFaczFQaWk1VWx1emNSV1Y3V3dFX0tyN2M?oc=5","date":"2026-03-31","type":"regulatory","source":"TipRanks","summary":"MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential - TipRanks","headline":"MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPWWlpZXhIeVl0MEVvYjNiOHZZaE9odVIxMlREVTZybGtNVTlURjVINmMyemtpZ0Jyd3NfMW1jUXdmTjFmUzRDd2JRVzJDNU5KbDZUSW92dHZnenZpZXV2RnB3bXk4OVdSSGFuaV9CeTkyMTE1amVhT0NzczdvZWtSZmhFeF9MLTFWMUVvR1pQTzF2YlRlQ1dlaXMzSWVaTWpuaFVZY0lEc09mRlJlaUNEYjhnTVVteTAwRGstbG85YTVnRTlCa0NUeE43WW1hUQ?oc=5","date":"2026-03-31","type":"earnings","source":"marketscreener.com","summary":"MaaT Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com","headline":"MaaT Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQSjZwdDRaRVJsNzBfdFZFOE1QU2VWaXR5bUlWZ280aTl4QmlwOFB0eTlFQ1RBTFg5aTdra0hodEM5N3BXN2JIdnlka2luTFdxRWp5Vkt4QTFlNDVrOTFXbG5zVDh5TGdXVF83UWF3UEVwX3dLQnEyS3YyV2ZNRFc0OUtxVnJpaDVOaW9HZEZGbGR4TUVrYUJRay1hNzR5YW92djA3dw?oc=5","date":"2026-03-30","type":"pipeline","source":"Yahoo Finance","summary":"MaaT Pharma Announces 2025 Annual Results and Provides Business Updates - Yahoo Finance","headline":"MaaT Pharma Announces 2025 Annual Results and Provides Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNaktnaWlYM3p1am5YMHB3ZlB1NnZSZE9XdGJKTGhtVW5HS3h6WWVsNnFtYjF3dDRGeWhTS3pwNldGdkpZRzR3RUxkQzNxM1BKY25lUXZIdm5kX3NRYUUyWWpSTmk2T2FQbVBBdld2eGxaRzl1WXNzTlp0elF6V3k5bjc4MWpjaHBQRS1XZ1ZURVp5a3k1LS1SSnAxbUpIaXRENDllRVl4ZllxWTA?oc=5","date":"2026-03-25","type":"trial","source":"meyka.com","summary":"Phase 3 lifts outlook: MaaT Pharma MAAT.PA Euronext pre-market Mar 2026 earnings - meyka.com","headline":"Phase 3 lifts outlook: MaaT Pharma MAAT.PA Euronext pre-market Mar 2026 earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPb0hOUEpZallBcm9iME1nWjlVRUdwVmtzTXZmSWh0Sml4R0NCSmpFcHlXMW1oRHNuQUNFVVJEbmNZbDZ0YmRmVlE5NVViSjlVRlZwa1E2OWVJdFkxTXZRNE0xVmtKbkt5T3J3NzJyUk01blZMLWJ3elpVMW9POTEwVTRHNU1zTnhBNmlqcFJIY0RRcWtxeDFfZ2YtOU1FdXlQS0ViaVFzMnY1enVCQWJ1cjc0dHlvMEV0dFRB?oc=5","date":"2026-03-23","type":"trial","source":"Investing.com","summary":"MaaT Pharma presents phase 3 trial results for aGvHD treatment - Investing.com","headline":"MaaT Pharma presents phase 3 trial results for aGvHD treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxNZ2RUNFc5LTBDMmNyeU1OOGFGcW9sWWc4MjRYZVFqeThrX1h4c3g0dVA3d24zbUNJbFFxVkpyQ2dGSG5lVlRpMW5OLUxzMzhOa1ZiUnN3MjdtazRGVTFEb0U5b1NEcTR3a2NBckItOXAySVVybHIybnpKR3RoYU96RHdnTlE5RXh6VFE0VW9ySWctZnJBMGV3MFpqeXZtYThpdGVHd0w4VVllZ2J1YTdFbDh6MEFKT1JfSHp2MHFNYWtxcW9xUnk4VG9LQzRHTTQtbF8zYUhhS3AzaDNDa0M5ZHM5bTlYWU01WWc5T2MweGYxV1NtRTdES0N1WmtiUUFpSWhLYUkzRF85b3ZXLVU4bndkVlg0U01VSi0xQ18xSExBM0hTM0VLYl9lamVKanJ3QUN6Sm0wVXRHMlg4VFRRYm83dW5BV2ZWbENZeXVpd3QtTFFFY2xkLXdjeVlYc0hHTmN6cw?oc=5","date":"2026-03-23","type":"trial","source":"businesswire.com","summary":"MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52 - businesswire.com","headline":"MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOWVBSOGNXY1ZNVHNWaFh6d1J1Y1p0NEItR3QxUkxnTHc0VTcxU2hNRDRKOWQwWWw5SEcwdmFBdklpMFVVRTFIWDJKZDVxcUhQaTdneHZwc1ZjNm8tS3JUSkJjaHRfd3EtZlRmVUJ6QTFrT1hSMHh2SWdiUkYtbVhtSTJqaXc2ZFc4SHIzOGdYdFVHZUlGNHYzUkQ3eHFLSllXRzN2WXpmU0Z4ODJXN3Q1MTBBcmhtV1BkelVTYXRPM2NqOGQwZnI4TjRzUGJmSnRPdWhQeDc3WjB6UnlzX0tUQllKSFEwZw?oc=5","date":"2026-03-09","type":"pipeline","source":"PharmiWeb.com","summary":"MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meetin - PharmiWeb.com","headline":"MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meetin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOdmVXV1BJVW5JT1BBcW4yLXg1RjZfWUNhQS02OFRuQmpMbzk2VlpuV3R0bVVXd0k0M1dWTDZwaW9kTFlFUXBobWpBMzBmSjFlQUxsR3ZwX3h6VGVoLWFHaHVwQmtZb0lBd0k3c1YwU0lMd2dGUnNYbW9hdWFIUGhIcFhKdjI2U2lhMGVIOEF0QUE?oc=5","date":"2026-02-03","type":"pipeline","source":"Yahoo Finance","summary":"MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital - Yahoo Finance","headline":"MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxNUFVqaXpNRmx0OUd6YjMzQXpsQWtXcE5Sd2FKaERkQVV5WUR4REZHc2hrTl9qMzJPMzZ6ZnlzVGNKd19GZTBsM2xfOFlHMXBpWHI2VFBpa09xWEd3U1RaU1NHY1RtVDJkMTJLcmViSE95UFR6SnFoWld0WUlVUlR1T1R2RTFKS1dEZEh3SXdvTHJhRVc3WUdXY1ZHdWVmeE9oZWEyd3hjb3Z2S1FoSWF3LXRkLWs1WTZhak1MNWhadjNiWFRhZ2huaWlCRTJWOWpjUk9aa0tVN3Y4cUwyOE1qU0FyTVJJQ2hrSHRmWXlhY3l2ZnhTZHBnMlJjZ00zNS0wcEpTcVUzYkZ4VmF6ZW81UFhHemQ2QWFHZWdlU0hPOGRhdWNxSWxiNUdDVnNqTmF0RC1KSQ?oc=5","date":"2025-12-08","type":"pipeline","source":"businesswire.com","summary":") in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival - businesswire.com","headline":") in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-21","type":"earnings","source":"simplywall.st","summary":"MaaT Pharma Reports First Half 2025 Earnings - simplywall.st","headline":"MaaT Pharma Reports First Half 2025 Earnings","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-05","type":"pipeline","source":"simplywall.st","summary":"Analysts Expect Breakeven For MaaT Pharma SA (EPA:MAAT) Before Long - simplywall.st","headline":"Analysts Expect Breakeven For MaaT Pharma SA (EPA:MAAT) Before Long","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}